Glaukos Corporation
GKOS
株式のランク
#2022
Glaukos Corporation operates as an ophthalmic medical technology and... Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
株価
$174.03
最終同期: 2026-10-20
時価総額
$10.26B
変化（1日）
4.34%
変化（1年）
129.35%
国
US
取引 Glaukos Corporation (GKOS)
カテゴリー
Healthcare
Glaukos Corporation（GKOS）の収益
Jun 2026 時点の収益 TTM: $612.84M
Glaukos Corporation の最新の財務報告によると、現在の収益 (TTM) は $612.84M です。2023 年には $314.71M の収益があり、これは 2022 年の $282.86M と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Glaukos Corporation の収益履歴（2012 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $612.84M | 59.81% |
| 2024 | $383.48M | 21.85% |
| 2023 | $314.71M | 11.26% |
| 2022 | $282.86M | -3.79% |
| 2021 | $294.01M | 30.70% |
| 2020 | $224.96M | -5.07% |
| 2019 | $236.98M | 30.73% |
| 2018 | $181.28M | 13.83% |
| 2017 | $159.25M | 39.21% |
| 2016 | $114.40M | 59.55% |
| 2015 | $71.70M | 57.28% |
| 2014 | $45.59M | 117.64% |
| 2013 | $20.95M | 762.33% |
| 2012 | $2.43M | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $46.59B | 7,501.51% |
US
|
|
| $35.48B | 5,690.10% |
IE
|
|
| $25.84B | 4,115.95% |
US
|
|
| $21.00B | 3,326.02% |
US
|
|
| - | - |
DE
|
